Ulcerative Colitis

There was a 25% relative reduction and a 0.3% absolute reduction in prevalence-adjusted index surgery rates for Crohn’s disease between 2007-2016.

Malnutrition rates were similar between patients with ulcerative colitis and patients with Crohn’s disease.

Maia Kayal, MD, explains how treatment guidelines can be used to direct and standardize treatment approaches in patients with ulcerative colitis.

Maia Kayal, MD, and David P. Hudesman, MD, discuss the importance of efficacy and safety data in the management of patients with ulcerative colitis and how this impacts treatment choice.

There were 248 patients included in the study with genetic data, with no differences found in mean titer after 2 or 3 doses between carriers and non-carriers of HLA-A24 associated with severe disease during COVID-19 infections.

Mesalamine use was linked to fewer relapses in the ulcerative colitis or IBD-unclassified cohorts compared to patients with Crohn’s disease.

Experts in gastroenterology provide an overview of induction vs maintenance therapy options, and comment on how their approach to treatment differs in patients with disease remission.

Maia Kayal, MD, and David P. Hudesman, MD, review their approaches to treatment in patients with ulcerative colitis.

Clinical remission at week 4 and the steroid dose reduction rate at week 4 were linked to medication discontinuation within 12 weeks.

Drs Maia Kayal and David P. Hudesman provide an overview of the treatment landscape for the management of ulcerative colitis, highlighting efficacy and safety considerations.

An expert in gastroenterology shares her opinion on the current unmet needs and treatment challenges for patients with ulcerative colitis.

Endoscopic subscores can determine whether a patient is a suitable candidate for dose reduction.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.

Some noticeable presenting features included jaundice, vomiting, and diarrhea.

David P. Hudesman, MD, explains the differences between active and inactive disease and discusses the role of early ulcerative colitis detection in the optimization of patient care.

Maia Kayal, MD, and David P. Hudesman, MD, highlight the burden of disease and comment on the impact ulcerative colitis has on a patient’s quality of life.

Aluminum internalization was correlated with inflammatory status in Caco-2 cells.

Patients with IBS more commonly had provisional post-traumatic stress disorder, IE, and bowel problems following antibiotic use.

In the study, 2.10% of patients with Crohn’s disease and 1.90% of patients with ulcerative colitis were diagnosed with colorectal cancer.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

Repeated metabolite monitoring with subsequent dose optimization resulted in 67.2% of patients achieving therapeutic levels after 1 year and 87.8% of patients achieving steroid-free remission, while 90% had no therapy escalation or surgery.

There was a direct association between consuming honey, ham, seafood, organ meats, salt, fruits on trees, fruit juice, olive, and nuts and the probability of developing IBD and ulcerative colitis.

Overall, 61.8% of patients on their first biologic agent reported clinical remission.

The majority of cases do not require the modification of therapy because it does not negatively affect the course of COVID-19.

The overall prevalence of NAFLD was 40.6%, with every NAFLD patient having a BMI of at least 25.